Find an Article

Filter articles

Applied Filters

Showing 231 to 240 of 338 results

IPR and biopharma patents: what the statistics show

International26-11-2015Melissa Gibson and Ruben Munoz

Fewer IPR petitions are instituted against biotech and pharma patents, and there is a higher survival rate of instituted claims in final written decisions compared to all technical fields combined. Melissa Gibson and Ruben Munoz of Akin Gump analyse the statistics.

Ten tips for generating a life sciences brand name

US19-11-2015Christina Martini and Virginia Wolk Marino

The proliferation of brands, combined with the financial and PR consequences of a potential rebrand in the event of infringement, has made selecting a trademark trickier than ever. Christina Martini and Virginia Wolk Marino of DLA Piper report.

CRISPR: careless talk costs patents

US29-10-2015Catherine Coombes

Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

Patent eligibility: Are biomedical patents under threat?


Lawyers have claimed that the latest ruling in Ariosa Diagnostics v Sequenom creates an “existential threat” to biomedical patents in the US, but is this really the case? LSIPR investigates.

Biosimilars: Twisting and turning


In July the US Court of Appeals for the Federal Circuit sought to clarify the rules on the ‘patent dance’, but with confusion reigning there are likely to be more twists and turns to come, as LSIPR finds out.

Animal patents: Blurring the lines

EU, US27-10-2015

Patent examiners not only have to tackle legal questions, but in cases of inventions directed to genetically modified animals they must consider moral issues too. This forms part of a wider controversial debate surrounding animals and patents. LSIPR reports.

Amgen v Sandoz: The biosimilars saga continues

US27-10-2015Steve Coyle and Leslie-Anne Maxwell

Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe.

Drug patents: A question of morality


Non-profit organisation I-MAK is attempting to expose the problem at the heart of the patent system—that too often drug patents are wrongfully granted and consequently sick people in poorer countries are being left untreated. LSIPR delves deeper into the issues.

Technology transfer: Centres of IP excellence

Brazil27-10-2015Gabriel Di Blasi and Felipe Barros Oquendo

The future of Brazil’s technological innovation centres, which bring together public and private sector parties to develop mainly life sciences technology, looks bright. Gabriel Di Blasi and Felipe Barros Oquendo of Di Blasi, Parente & Associados report

Interpol: clamping down on pharma crime

International01-10-2015Aline Plançon

The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports.

Showing 231 to 240 of 338 results